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Introduction
Cervical cancer is one of the three major malignancies in
women worldwide1 with half a million new cases diagnosed
each year. In the UK alone there are, on average, 3200 new
cases a year, resulting in approximately 1200 deaths. 
Cervical cancer is the eleventh most common cause of
cancer deaths in women in the UK, representing
approximately 2% of all female cancers. There is strong
epidemiological evidence to show that acquisition of high-
risk human papillomavirus (HPV) phenotypes (i.e., HPV 16,
18, 31 and 33) is important in the development of cervical
cancer,2 and this group has been found in no less than 75%
of cervical tumours.3
As a result of the mass-screening programme in place in
the UK, a substantial decrease in the incidence of cancer
occurred between 1988 and 1997, representing a fall of 42%.
Whereas there were 10.4 cases per 100,000 in 1995, by 1999
the prevalence had dropped to 9.3 per 100,000. 
A significant drop in the number of cancer cases has been
achieved by the implementation of Papanicolaou (Pap) smear
screening, which aims to detect a series of precancerous
cytological changes termed cervical intraepithelial neoplasia
(CIN).4,5 Identifying cervical cytology changes in
conventional Pap smears involves taking a sample of cells
from the transformation zone of the cervix, using a spatula or
cytobrush. The cells collected are transferred to a microscope
slide, fixed in alcohol, stained with a Papanicolaou technique,
and then screened microscopically. 
Identification of pathology in the transformation zone
relies heavily on the skills of cytoscreeners, biomedical
scientists and pathologists; however, the quality of the
preparation can be compromised by the presence of
inflammatory exudate, inadequate cellularity, or failure to
sample the transformation zone adequately. In order to
overcome some of these problems, liquid-based cytology
(LBC) methodology has been developed, in which the
patient’s entire cervical cell sample is rinsed into a vial
containing a preservative, and slides are then prepared for
examination from the fluid sample. The advantages of LBC
include more uniform specimen cellularity and the fact that
there are fewer fields to examine. 
The advantage of the polymerase chain reaction (PCR) 
as a diagnostic tool is its sensitivity, making it an ideal means 
of detecting low copy numbers of HPV DNA. Care and
attention is required to avoid contamination of individual
samples during collection and subsequent processing. 
In theory, 30–40 cycles can produce a million-fold
amplification and the sensitivity is such that a single copy of
HPV DNA can be detected. Samples of DNA isolated from
Pap smears and paraffin wax-embedded specimens may be
used as a template. 
Two sets of primers (GP5+/GP6+6 and MY09 and MY117)
have been used extensively for HPV detection. Numerous
HPV types have been implicated in cervical cancer, although
HPV types 16, 18, 31 and 33 are most common. Thus, to be
able to detect a broad spectrum of HPV types and yet be able
to distinguish individual serotypes, Ting and Manos7
devised a pair of consensus primers that shared interspersed
regions of DNA sequence homology, especially within the
open reading frames (ORF) of the E1 and L1 genes. These
workers identified regions of homology 20–25 bp in length,
from which consensus primers that would amplify DNA
from more than 25 types of genital HPV were designed. 
The primers (MY11 for the positive strand and MY09 for
the negative strand) are degenerate in several positions,
which allows the possibility that more than one nucleotide
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can be inserted at a specific time. The size of the product
obtained allows determination of the HPV type as shown 
in Table 1. 
As the composition of the LBC medium in which cervical
cells are preserved is unknown, the present study aims to
determine the usefulness of this method in the diagnosis 
of HPV by an in-house PCR amplification method using 
the MY09/MY11 primers described above. Furthermore,
characterisation of products is performed through DNA
sequencing of the amplicons generated. 
Materials and methods
A total of 38 LBC samples were collected randomly from
apparently healthy patients (age range: 18–56; mean: 35
years) undergoing routine cervical cytology.
Oligonucleotide primers for the detection of HPV types
were synthesised and used according to the manufacturer’s
instructions (Invitrogen). The final concentration of primers
used in each reaction was 0.5 µmol/L. 
The sequence of the primers were as follows: MY 11
(positive strand primer) 5’ GCM CAG GGW CAT AAY AAT
GG 3’; MY09 (negative strand primer) 5’ CGT CCM ARR
GGA WAC TGA TC, where M= A + C, R = A + G, W = A +
T, Y = C +T.
DNA was extracted by an in-house method. Briefly, 1 mL
well-mixed LBC fluid from each patient was transferred into
1.5 mL Eppendorf tubes using sterile disposable pipettes.
The tubes were capped and centrifuged at 3500 rpm for 
10 min. The supernatant was removed and 1 mL lysis buffer
(10 mmol/L Tris [pH 7.4] containing 1 mmol/L EDTA, 1% SDS
and 20 µL 10 mg/mL proteinase K) was added to the deposit
containing the cell pellet. The mixture was homogenised by
vortex-mixing and incubated at 65˚C for 1 h. 
The buffer containing proteinase K lyses cervical cells,
which allowed both human and HPV DNA to be extracted.
The tubes were then heated at 95˚C for 1 min to inactivate
the proteinase K, and then cooled. The lysed material was
divided into two Eppendorf tubes, one of which was 
kept at –70˚C for future use. To each of the remaining tubes,
1 mL phenol:chloroform:isoamyl alcohol (25:24:1 [v/v];
Sigma) was added, the contents were mixed and 
centrifuged at 3000 rpm for 10 min. The top layer was
carefully removed and transferred to a new tube and an
equal amount of chloroform was added, mixed and spun at
3000 rpm for 10 min. 
The top layer was removed carefully into a clean tube and
two volumes of cold 95% ethanol and 5 µL 3 mol/L sodium
acetate buffer were added, mixed well and kept in the
freezer at –20˚C for 1 h. This last step permits the
precipitation of DNA. The tube was then spun at 10,000 rpm
for 10 min to pellet the extracted DNA and the supernatant
was removed and discarded. 
Then, 100 µL 70% ethanol was added to the pellet
(without mixing) and the tube spun at 10,000 rpm for 5 min. 
The supernatant was removed and discarded. 100 µL of 95%
ethanol was added to the pellet (without mixing) and
centrifuged at 10,000 rpm for 10 min. The supernatant was
removed and discarded. The pellet was allowed to air dry in
a sterile incubator, following which the DNA pellet was
resuspended carefully in 50 µL sterile distilled water.
HPV DNA amplification was carried out in a Perkin Elmer
480 DNA thermal cycler (Perkin Elmer, Baltimore , USA) and
PCR master mix (Promega, Southampton, UK) was used 
in 25 µL reactions (Table 2). The constituents were added to
a 0.5 mL Eppendorf tube, mixed briefly by vortex-mixing
and then centrifuged at 2500 rpm for 30 sec. The reaction mix
was then overlaid with 20 µL sterile mineral oil, capped, 
and transferred to the thermal cycler for amplification.
Thirty-five cycles of PCR were carried out using the cycling
conditions described in Table 3 
A negative control consisting of water instead of template
DNA and a positive control consisting of DNA extracted
from HeLa 229 cells infected with HPV 18 were also
included. 
Using a micropipette, 10 µL PCR amplicon was removed
carefully from the 0.5 mL Eppendorf tube into a fresh tube
containing 2 µL 6x loading dye (Promega). The mixture was
loaded into the wells of a pre-cast 1% agarose gel in 1x TBE
(89 mmol/L Tris, 89 mmol/L boric acid, 2 mmol/L EDTA [pH
8.3]) submerged in a Bio-Rad electrophoresis tank
containing 1x TBE buffer. Also, 10µL 100 bp DNA ladder
mixed with 2 µL loading dye was included for size
comparison. A voltage of 100 V was applied for 1 h to permit
electrophoretic migration. 
The gel was removed and stained in 100 mL 1x TBE buffer
to which 10 µL (10 mg/mL) ethidium bromide was added.
The gel was allowed to stain for 10 min and then washed 
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Table 1. Position of first bases and size of HPV.
HPV type First base position Product size 
MY11 primer MY09 primer of L1 gene (bp)
HPV06 6722 7170 448 
HPV11 6707 7155 448
HPV16 6584 7035 451
HPV18 6558 7012 454
HPV33 6539 6987 448 
Table 2. PCR conditions for HPV DNA amplification.
Ingredients Volume (µL) 
Primer MY09 (x10) 1
Primer MY11 (x10) 1 
Template DNA 1.5 
PCR Master Mix 12.5 
Nuclease free water 9 
Total volume 25 
Table 3. Thermal cycling conditions for MY09/11 primers.
Step Temperature (˚C) Time (min)




Final extension 72 5
in distilled water. Ethidium bromide intercalates with the
DNA bases, which then fluoresce under ultraviolet (UV)
light from a transilluminator.
Results
Table 4 illustrates the age distribution of the patients tested. 
Cytopathology
The results of cytopathological examination were presented
as four outcomes: normal (no dyskaryosis), borderline
changes, mild dyskaryosis, moderate-severe dyskaryosis.
The distribution is illustrated in Figure 1. Among the cohort
47% were normal, 16% showed borderline changes
requiring a further smear in six months, 16% showed mild
dyskaryosis and 21% showed moderate to severe
dyskaryosis (CIN 3). 
Molecular detection of HPV
High-grade HPV was detected in 12 out of 38 samples (32%).
The 33–37 age group produced the highest number of
positive samples. Examples of the positive amplicons are
shown in Figure 2. 
Discussion
In the present study, all the patients who had moderate 
or severe dyskaryosis on cytology were also positive for
high-grade HPV by the in-house PCR method used.
However, two cases of mild dyskaryosis did not give a
positive result with PCR. This suggests that either they were
HPV-negative or that the virus was present but not detected
(i.e., they were false-negatives) because HPV load was below
the level of detection for the method. This could be verified
by increasing the amount of target DNA in the amplification
or increasing the number of amplification cycles to 40. 
In contrast, failure to detect HPV could be attributed to the
fact that the set of consensus primers used did not detect
HPV 31, which is also associated with cervical cancer, and
could have been the cause of the dyskaryosis in these two
cases. DNA degradation is another possibility that should be
investigated by using a set of primers that target a
housekeeping gene (e.g., β-actin) in human chromosomal
DNA. However, this would only determine whether or not
integrated viral genes were intact, as it would yield no
information about unintegrated virus. 
Clearly, samples should be analysed with a different set 
of HPV-specific primers but further negative results could 
be interpreted in three ways: either viral DNA was not
present or extraction was inadequate or the product was
degraded. The last possibility is unlikely because all 
the samples were collected and stored under similar
conditions and those that were amplifiable gave a good yield
of amplicons. 
Overall detection rate of high-grade HPV in dyskaryosis
was 86%. This correlates well with the results of other
studies and implies that dyskaryosis in 10% of patients is not
the result of viral infection. Thus, the two negative cases
described may represent patients in whom dyskaryosis was
not a consequence of high-grade HPV infection. 
The purpose of the present study was to evaluate the
performance characteristics of LBC in detecting HPV, as
studies of the ThinPrep system (Cytyc, Boxborough, MA,
USA) have shown that it was possible to detect the presence
of HPV DNA by PCR from patients undergoing routine
cervical cytology examination. Although the composition of
the medium in which the cells are preserved is unclear,
BRITISH JOURNAL OF BIOMEDICAL SCIENCE 2004 61 (1)
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Table 4. Age distribution of patients.
Age group (years) 18-22 23-27 28-32 33-37 38-42 43-47 48-52 53-57
Patient numbers 4 5 6 11 7 1 1 3
Fig. 1. Cervical pathology of the cohort. Fig. 2. Separation of amplicons on 1% agarose gel. Lane 1: 100 bp
DNA (1000 bp standard band indicated); lane 2: positive control;
lane 3: negative control; lanes 4–8: amplicons from patient samples.
The amplicon sizes are slightly less than 500 bp, corresponding to
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nothing present appeared to interfere with the in-house
PCR technique used in the present study. However, in order
to remove potential inhibitors, it is advisable to separate the
cervical cells from the medium by centrifugation, discard the
medium and then wash the cells in isotonic saline before
proceeding to DNA extraction. 
Material isolated from LBC has also been tested in hybrid
capture assays. A study by de Cremoux et al.8 investigated
the efficiency of the Hybrid Capture 2 (HC2; Digene,
Gaithersburg, MD, USA) HPV assay for the detection 
of cervical neoplasia in LBC. All patients were screened 
by both conventional Pap smear and ThinPrep LBC (Cytyc).
HPV DNA was detected in the residual liquid-based
material; however, their results included 111 false-positives
(34 cross-reactions [1.90%] and 77 true false-positive
[4.31%]), which were attributed to a contiguous strong
chemiluminescence signal. Although they concluded that
the HC2 assay was a reliable and sensitive test for HPV DNA
detection, they did not advocate its use for large-scale
screening for cervical neoplasia. 
The in-house method used in the present study did not
produce any false-positive reactions, is suitable for
modification to a microtitre plate format (substituting an
automated capillary detection system for the agarose gel),
and could be adapted for real-time PCR platforms 
to determine viral load.
There are numerous advantages to the use of LBC. 
In addition to detecting precancerous changes in the cells in
solution, adequate material remains on which to test for the
presence of HPV. Although changes in the transformation
zones are caused mainly by HPV, it has been suggested that
other organisms, such as Chlamydia trachomatis9,10 and
Trichomonas vaginalis,11-14 may also be involved. 
Currently, this group is studying the feasibility of
detecting C. trachomatis and T. vaginalis from LBC samples 
by in-house PCR. 
Conclusions
Following National Institute for Clinical Excellence approval
of the use of LBC in the NHS Cervical Screening
Programme,15 the results of the pilot study presented here
show that DNA extracted from the LBC medium can be used
in molecular diagnostics. HPV DNA was detected in 32% 
of the cohort undergoing routine Pap screening and in 
86% of those with dyskaryosis. However, investigation of a
larger cohort is needed in order to fully appreciate the value
of the in-house PCR used, but it is anticipated that a fully
developed and tested in-house PCR would lower the cost 
of HPV testing considerably.
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